BioAdaptives (BDPT) Stock Price, News & Analysis

BioAdaptives, Inc. (BDPT) is a biotechnology and health and wellness company that focuses on developing nutraceutical and dietary supplement products for humans and animals. According to recent company announcements, BioAdaptives works with evidence-based formulations that draw on botanicals, adaptogens, amino acids, and other nutraceutical ingredients to support areas such as cognitive performance, weight management, and pet wellness.

BioAdaptives’ products are positioned within the consumer health and wellness space, with an emphasis on science-driven development and clinical validation. The company highlights the use of human and veterinary trials, third-party testing, and regulatory-compliant manufacturing practices to support the quality and safety of its offerings. BioAdaptives’ shares trade on the over-the-counter market under the symbol BDPT.

Human cognitive and performance support

BioAdaptives has introduced several nootropic and cognitive-support products. The company announced the commercial availability of MyndMed™, described as a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. MyndMed™ is intended to support short-term alertness and calm focus, mid-term synaptic efficiency and cognitive processing speed, and long-term cellular energy, antioxidant balance, and neuroprotective support.

The company states that MyndMed™ brings together well-studied nutrients to support cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity. It is manufactured in the United States in cGMP-certified facilities, with third-party testing for identity, purity, and heavy metals, and uses transparent labeling without proprietary blends. BioAdaptives notes that the formulation is designed to remain compliant with World Anti-Doping Agency (WADA) regulations.

BioAdaptives also announced NeuroRush™, described as an adaptogenic nootropic intended to support sustained cognitive performance, mental clarity, stress adaptability, and long-term brain health. NeuroRush™ is presented as a plant-based, adaptogen-focused formula that combines clinically studied ingredients such as Rhodiola Rosea, Ashwagandha, Bacopa Monnieri, Panax Ginseng, and Mucuna Pruriens. The company indicates that NeuroRush™ is designed for professionals, students, athletes, and older adults seeking enhanced mental performance, and that it targets multiple pathways involved in brain function, dopamine balance, neuroplasticity, and mental endurance.

Weight management and metabolic support

Another key focus area for BioAdaptives is weight management. The company has highlighted Zeranovia™, a weight management product that has undergone dosage trials and is the subject of a human clinical trial approved by an Institutional Review Board (IRB). According to BioAdaptives, Zeranovia™ is based on a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, four of which are adaptogens.

In a dosage trial described by the company, participants experienced weight loss with minimal and manageable side effects. BioAdaptives reports high participant satisfaction and has stated that it is proceeding with additional clinical stages. The company emphasizes that relatively few nutraceutical products undergo human clinical trials and presents Zeranovia™ as an effort to provide weight management support with scientific backing.

Pet wellness and regenerative support

Through its pets division PawPa™, BioAdaptives has developed products aimed at animal wellness, particularly for aging or injured dogs. The company has announced Pawpa™ Regen and Regen Dog Chews, canine supplements formulated with nutraceuticals and natural ingredients that are described as supporting the release of circulating stem cells and regenerative healing.

According to BioAdaptives, Regen Dog Chews have been evaluated in veterinarian trials and canine studies, where increases in circulating stem cells and improvements in dogs’ wellness metrics were observed. The company developed the APBAR® rating system (Appearance, Performance, Behavior, Attitude and Responsiveness) as a tool for pet owners to track visible changes in their dogs’ condition, such as coat quality, mobility, stamina, mood, and responsiveness. The products are described as veterinarian-recommended, crafted from all-natural ingredients, and safe, with no adverse effects reported in the trials cited by the company.

Quality, compliance, and testing

BioAdaptives places repeated emphasis on quality control and compliance in its public communications. For MyndMed™, the company notes manufacturing in cGMP-certified facilities, third-party testing, and transparent labeling. It further reports that MyndMed™ has been tested by TruShield™ Laboratory Services, a sports supplement testing provider specializing in WADA compliance, and that TruShield™ confirmed the absence of WADA-prohibited substances. This clearance is described as enabling use by competitive athletes, including those associated with organizations such as the Ultimate Fighting Championship® (UFC).

For its weight management and pet wellness products, BioAdaptives references IRB-approved human clinical trials (for Zeranovia™) and veterinarian trials and canine studies (for Regen Dog Chews). These references support the company’s stated goal of supplying products with “provable scientific results” and distinguish its approach from nutraceutical offerings that do not undergo formal clinical evaluation.

Leadership and strategic direction

BioAdaptives has highlighted changes in leadership and advisory personnel as part of its strategic evolution. The company reports that it appointed James Keener as CEO, with a focus on products that are in demand and can significantly impact users’ lives. It has also announced additions to its Board of Advisors and Board of Directors, including individuals with backgrounds in athlete development, mixed martial arts promotion, and leadership roles at large consumer and entertainment companies. These appointments are presented by BioAdaptives as support for its efforts to expand its reach in health, wellness, and performance markets.

Product development pipeline and market approach

In its public statements, BioAdaptives has described a pipeline of multiple products prepared for phased entry into the nutritional marketplace. The company notes that several products benefited from development work and funding prior to being brought under the BioAdaptives umbrella, enabling staged rollouts over a defined period. Distribution channels referenced include direct-to-consumer e-commerce, select online retailers, and partnerships with health and wellness organizations.

Across its product lines, BioAdaptives emphasizes themes of adaptogenic support, natural ingredients, and scientific validation. Human-focused products such as MyndMed™, NeuroRush™, and Zeranovia™ are aimed at cognitive performance and weight management, while pet-focused offerings under the PawPa™ brand target regenerative wellness in dogs. The company’s communications position these products as alternatives or complements to more conventional options, while underscoring the importance of safety, compliance, and measurable outcomes.